Octarine Bio, the synthetic biology drug development company that produces psilocybin from sugar using fermentation, partners with clinical research organisation Clerkenwell Health to deliver clinical trials.
– Europe’s commercial psychedelic healthcare ecosystem is growing, building on a strong heritage of academic and civil society support
– A partnership between these two innovative startups leads the way for advancing patient access to psychedelic medicines in Europe
– Octarine Bio uses yeast fermentation to produce psilocybin from sugar which comes with many benefits such as low cost, sustainability, and supply chain stability
– Clerkenwell Health is well positioned to accelerate the psychedelic sector by offering …
Read the source article at sg.finance.yahoo.com